As of 2025-07-14, the Fair Value of Relmada Therapeutics Inc (RLMD) is -11.41 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.61 USD, the upside of Relmada Therapeutics Inc is -1,969.78%.
With the market price of 0.61 USD and our fair value calculation, Relmada Therapeutics Inc (RLMD) is not a good investment. Investing in RLMD stocks now will result in a potential loss of 1,969.78%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -59.46 | -125.75 | -157.04 | -98.79 | -79.98 | -104.20 |
| YoY growth | -243.30% | -111.49% | -24.88% | 37.09% | 19.04% | -64.71% |
| Market Cap (mil) | 20.25 |
| P/E | |
| Forward P/E |
| EPS | -2.28 |
| Avg earnings growth rate | -64.71% |
| TTM earnings | -75.71 |